HSV VACCINE FOR PATIENTS WITH GENITAL HERPES

用于生殖器疱疹患者的 HSV 疫苗

• 批准号: 6246151
• 负责人: CHARLES G PROBER
• 金额: $ 3.61万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-05-15 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6246151
• 关键词: Herpesviridae vaccine; clinical research; clinical trials; drug screening /evaluation; genital herpes; glycoproteins; herpes simplex virus 2; human subject; human therapy evaluation; placebos; recombinant virus

Under the direction of Dr. Prober, subjects have been enrolled in a trial evaluating the safety, immunogenicity, and efficacy of a recombinant vaccine against herpes simplex virus type 2 (HSV-2). This trial is a multicentered, randomized, placebo-controlled evaluation of a glycoprotein based vaccine developed by Chiron Biocine, Emeryville, CA. Enrollees were HSV-2 uninfected sexual partners of HSV-2 infected subjects. Interim evaluation of vaccine efficacy failed to demonstrate benefit and the study was prematurely discontinued by the sponsor. Nonetheless, T-cell recognition of common and type-specific HSX glycoproteins was measured in the 21 study subjects enrolled at Stanford and these responses currently are being analyzed so that they can be compared with the resposes of naturally infected individuals.

在Prober博士的指导下，受试者已入组 一项评价安全性、免疫原性和有效性的试验， 针对单纯疱疹病毒2型（HSV-2）的重组疫苗。 这 试验是一项多中心、随机、安慰剂对照的评价， 一种基于糖蛋白的疫苗，由Chiron Biocine，Emeryville， 约 入组者为HSV-2感染者的未感染HSV-2的性伴侣 科目 疫苗有效性的中期评价未能证明 受益，申办者提前终止研究。 尽管如此，T细胞识别常见和类型特异性HSX 在斯坦福大学招募的21名研究对象中测量了糖蛋白 目前正在对这些反应进行分析， 与自然感染者的反应相比。